Literature DB >> 18439064

Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model.

Azman Seeni1, Satoru Takahashi, Kentaro Takeshita, Mingxi Tang, Satoshi Sugiura, Shin-ya Sato, Tomoyuki Shirai.   

Abstract

Research into actions of resveratrol, abundantly present in red grape skin, has been greatly stimulated by its reported beneficial health influence. Since it was recently proposed as a potential prostate cancer chemopreventive agent, we here performed an in vivo experiment to explore its effect in the Transgenic Rat for Adenocarcinoma of Prostate (TRAP) model, featuring the rat probasin promoter/SV 40 T antigen. Resveratrol suppressed prostate cancer growth and induction of apoptosis through androgen receptor (AR) down-regulation, without any sign of toxicity. Resveratrol not only downregulated androgen receptor (AR) expression but also suppressed the androgen responsive glandular kallikrein 11 (Gk11), known to be an ortholog of the human prostate specific antigen (PSA), at the mRNA level. The data provide a mechanistic basis for resveratrol chemopreventive efficacy against prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18439064

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  35 in total

Review 1.  Resveratrol: Biological and pharmaceutical properties as anticancer molecule.

Authors:  Tze-chen Hsieh; Joseph M Wu
Journal:  Biofactors       Date:  2010 Sep-Oct       Impact factor: 6.113

Review 2.  Dietary factors and epigenetic regulation for prostate cancer prevention.

Authors:  Emily Ho; Laura M Beaver; David E Williams; Roderick H Dashwood
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

3.  Resveratrol-zinc combination for prostate cancer management.

Authors:  Chandra K Singh; Anna Pitschmann; Nihal Ahmad
Journal:  Cell Cycle       Date:  2014-05-27       Impact factor: 4.534

Review 4.  Resveratrol-based combinatorial strategies for cancer management.

Authors:  Chandra K Singh; Jasmine George; Nihal Ahmad
Journal:  Ann N Y Acad Sci       Date:  2013-07       Impact factor: 5.691

5.  Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments.

Authors:  Laura E Johnson; Jordan T Becker; Jason A Dubovsky; Brian M Olson; Douglas G McNeel
Journal:  Chin Clin Oncol       Date:  2013-03-01

Review 6.  Future directions in the prevention of prostate cancer.

Authors:  Ian M Thompson; April B Cabang; Michael J Wargovich
Journal:  Nat Rev Clin Oncol       Date:  2013-11-26       Impact factor: 66.675

Review 7.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 8.  Apoptosis by dietary agents for prevention and treatment of prostate cancer.

Authors:  Naghma Khan; Vaqar Mustafa Adhami; Hasan Mukhtar
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

9.  Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment.

Authors:  Vanna Sanna; Imtiaz Ahmad Siddiqui; Mario Sechi; Hasan Mukhtar
Journal:  Mol Pharm       Date:  2013-09-04       Impact factor: 4.939

10.  Repressive effects of resveratrol on androgen receptor transcriptional activity.

Authors:  Wen-feng Shi; Melanie Leong; Ellen Cho; Joseph Farrell; Han-chun Chen; Jun Tian; Dianzheng Zhang
Journal:  PLoS One       Date:  2009-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.